What is BioNexus Gene Lab Price-to-Operating-Cash-Flow?
As of today (2024-05-28), BioNexus Gene Lab's share price is $0.5199.
BioNexus Gene Lab's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.07. Hence, BioNexus Gene Lab's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for BioNexus Gene Lab's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 6 years, BioNexus Gene Lab's highest Price-to-Operating-Cash-Flow Ratio was 25560.00. The lowest was 19.32. And the median was 300.00.
BioNexus Gene Lab's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.07.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of BioNexus Gene Lab was -328.10% per year.
BioNexus Gene Lab Price-to-Operating-Cash-Flow Historical Data
The historical data trend for BioNexus Gene Lab's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab Price-to-Operating-Cash-Flow Chart
|
BioNexus Gene Lab Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
431.25 |
25,560.00 |
300.00 |
- |
|
BioNexus Gene Lab Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
202.46 |
60.27 |
- |
- |
- |
Competitive Comparison of BioNexus Gene Lab's Price-to-Operating-Cash-Flow
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Price-to-Operating-Cash-Flow Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Price-to-Operating-Cash-Flow falls into.
BioNexus Gene Lab Price-to-Operating-Cash-Flow Calculation
BioNexus Gene Lab's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.5199 | / | -0.073 |
| = | |
BioNexus Gene Lab's Share Price of today is $0.5199.
BioNexus Gene Lab's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
| Chak Hua Yew |
director |
1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
| Yeat Min Fong |
director |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Teng Fook Fong |
director |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Chee Keong Yap |
director |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Boon Teong Teoh |
director |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Yee Meng Wong |
director, officer: President |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Wei Li Leong |
officer: Chief Financial Officer |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Chai Ping Lin |
director |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Tai Tan Liong |
director, officer: Chief Operating Officer |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
| Sook Keng Yeoh |
director, officer: Chief Executive Officer |
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200 |
BioNexus Gene Lab (BioNexus Gene Lab) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your